Metabolic syndrome
Diabetes mellitus type-2
- incidence +30% since 1990
- persons in their 30s: +70%
- health care expenditure: more than cancer
- preceded by insulin resistance

- often associated with diabetes
- incidence approx. 25%
- even if treated, yet higher mortality

Associated metabolic disorders
- hypertriglyceridemia
- hyperuricemia
- many others

Unfavourable lifestyle
Unhealthy diets
BMI calculation
BMI and BP
Salt intake



Hyperkinetic HT

Established HT

Systolic HT

Renin / Angiotensin II

Diabetes type-2
Insulin resistance
Diabetes type-2
Metabolic syndrome

Imidazoline receptors

Home page

International Society for Molecular Nutrition and Therapy

other sites maintained by us:
The site focusses on links between lifestyle, sympathetic overactivity and cardiovascular disease. Therapeutics are described which counteract sympathetic overactivity by reducing catecholamine release: the centrally acting imidazoline I1 receptor agonist moxonidine and the angiotensin receptor blocker (ARB) eprosartan with a high presynaptic inhibitory action on norepinephrine release.

Since eprosartan has a unique structure, i.e. the first non-tetrazol and non-biphenyl ARB, it differs from other ARBs by inhibiting more potently presynaptic norepinephrine release. Eprosartan controls high blood pressure by  a "dual mechanism of action". Based on this dual mechanism of action, the "Teveten Song - The Power of Two" has been composed and presented by the singers Ogie and Janno on occasion of the Teveten Launch in Manila, May 27, 2003.

An overview on the EXCESS CATECHOLAMINE SYNDROME can be downloaded as PDF.
An update focuses on "Addominal fat and sympathetic overactivity - from calorie intake to postmenopausal hypertension"

Please read this important disclaimer
  Copyright © 2001 by Rupp
Updated December 14, 2013